arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Galectin Therapeutics Inc.

GALT Health Care Biotechnology: Pharmaceutical Preparations
$4.76
▲ +3.2% Today
as of Sep 4, 16:49 ET
Last 30 days +36.39% Jul 27 → Sep 04
$2.84 $3.31 $3.79 $4.27 $4.74 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$4.33
High
$4.72
Low
$4.33
Volume
$473,095
Avg Vol
$459,093
Mkt Cap
$360M
P/E (TTM)
—
Beta
—
52w High
$7.13
52w Low
$2.03
Div Yield
—
Shares Out
$66M

Recent Press Releases & News last 60 days · 2 items

Aug 14 · 12:00 PR GlobeNewswire
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Aug 4 · 12:00 PR GlobeNewswire
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Overview

52-week range
$2.03
$7.13
54% of range
Avg surprise (last 2)
-4.2%
Avg reaction (last 2)
-3.1%
50% positive
Latest IV / EM
465%
EM ±72.6% · $5 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.24$-0.20$-0.15$-0.10$-0.06 Actual $-0.19Actual $-0.15Actual $-0.24Actual $-0.19Actual $-0.20Actual $-0.18Actual $-0.15Actual $-0.12Est $-0.16Actual $-0.13Actual $-0.08Est $-0.06Actual $-0.14 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-11M$-10M$-8M$-7M$-5M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.14 — — — — financials
Fri May 15, 2026Mar/2026 $-0.08 $-0.06 -33.3% +46.7% -7.7% earnings
Tue Sep 30, 2025Sep 2025 $-0.13 — — — — financials
Thu Aug 14, 2025Jun/2025 $-0.12 $-0.16 +25.0% — — earnings
Thu May 15, 2025Mar/2025 $-0.15 — — — +1.5% earnings
Mon Sep 30, 2024Sep 2024 $-0.18 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.20 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.19 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.24 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.15 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.19 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-4M$-4M—$-4M$-5M$-8M—$-9M
Net income$-9M$-5M—$-8M$-8M$-10M—$-11M
EPS (diluted)$-0.14$-0.08—$-0.13$-0.12$-0.15—$-0.18

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$13M$14M$18M$12M$14M$7M$15M$27M
Inventory————————
Total current assets$15M$16M$19M$13M$15M$9M$17M$29M
Total assets$15M$16M$20M$13M$16M$10M$17M$29M
Long-term debt————————
Total liabilities$152M$146M$146M$136M$133M$122M$121M$121M
Total equity$-139M$-132M$-128M$-125M$-119M$-114M$-105M$-94M

Implied volatility — last 90 days

24%266%508%750%991% Jun 07 — IV 124% · EM ±17.2%Jun 08 — IV 174% · EM ±22.9%Jun 09 — IV 110% · EM ±13.7%Jun 10 — IV 302% · EM ±35.7%Jun 11 — IV 155% · EM ±17.1%Jun 12 — IV 211% · EM ±21.5%Jun 15 — IV 369% · EM ±26.7%Jun 19 — IV 112% · EM ±24.8%Jun 22 — IV 120% · EM ±25.0%Jun 23 — IV 157% · EM ±32.1%Jun 24 — IV 188% · EM ±37.7%Jun 25 — IV 129% · EM ±25.4%Jun 26 — IV 152% · EM ±29.2%Jun 29 — IV 148% · EM ±26.2%Jun 30 — IV 125% · EM ±21.5%Jul 01 — IV 180% · EM ±30.0%Jul 02 — IV 144% · EM ±23.3%Jul 03 — IV 149% · EM ±23.3%Jul 06 — IV 140% · EM ±19.4%Jul 07 — IV 156% · EM ±20.6%Jul 08 — IV 274% · EM ±34.4%Jul 09 — IV 179% · EM ±21.2%Jul 10 — IV 267% · EM ±29.6%Jul 13 — IV 181% · EM ±15.1%Jul 14 — IV 182% · EM ±13.2%Jul 15 — IV 151% · EM ±8.9%Jul 16 — IV 626% · EM ±26.1%Jul 20 — IV 153% · EM ±36.3%Jul 21 — IV 193% · EM ±44.9%Jul 22 — IV 285% · EM ±65.3%Jul 23 — IV 284% · EM ±63.8%Jul 24 — IV 222% · EM ±49.0%Jul 27 — IV 248% · EM ±51.8%Jul 28 — IV 281% · EM ±57.5%Jul 29 — IV 278% · EM ±55.7%Jul 30 — IV 272% · EM ±53.4%Jul 31 — IV 194% · EM ±37.0%Aug 03 — IV 279% · EM ±49.5%Aug 04 — IV 214% · EM ±36.9%Aug 05 — IV 242% · EM ±40.5%Aug 06 — IV 401% · EM ±64.9%Aug 07 — IV 297% · EM ±46.4%Aug 10 — IV 297% · EM ±41.1%Aug 12 — IV 369% · EM ±46.2%Aug 13 — IV 432% · EM ±51.0%Aug 14 — IV 460% · EM ±50.9%Aug 17 — IV 737% · EM ±61.6%Aug 18 — IV 785% · EM ±56.8%Aug 19 — IV 992% · EM ±58.6%Aug 24 — IV 25% · EM ±5.2%Aug 25 — IV 178% · EM ±36.3%Aug 26 — IV 42% · EM ±8.4%Aug 27 — IV 154% · EM ±30.2%Aug 28 — IV 170% · EM ±32.5%Aug 31 — IV 193% · EM ±34.2%Sep 01 — IV 35% · EM ±6.1%Sep 02 — IV 53% · EM ±8.9%Sep 03 — IV 135% · EM ±21.8%Sep 04 — IV 465% · EM ±72.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in